Among 286 PTC cases, three cases (1.0%) carried gain of function mutations, while in 289 CRC cases, two (0.7%) cases harbored gain of function mutations of MAP2K1 gene. This evidence concerns the gene MAP2K1 and colorectal carcinoma.